CANTIL
LOE ApproachingNDAORALTABLET
Approved
Nov 1956
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CANTIL is an oral small-molecule tablet approved in 1956 by Sanofi under NDA designation. The generic name and mechanism of action are not disclosed in available data. Patient population and indication profile require additional clinical documentation.
LOE Approaching
Product is in late lifecycle stage with moderate competitive pressure (30), indicating shrinking team size and transition focus toward managed decline or lifecycle extension strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CANTIL currently shows zero linked job openings, reflecting its LOE-approaching lifecycle stage. Career opportunities are concentrated in commercial roles focused on managed decline, cost optimization, and defending market share against generics rather than growth initiatives.
Brand ManagerField Sales Representative
Worked on CANTIL at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.